par Anaissie, Elias;Reiffers, Josy;Calandra, Thierry;Glauser, Michel;Klastersky, Jean 
;Gaya, Harold;Zinner, Stephen H.;Meunier, Françoise ;Rolston, Kenneth;Bodey, Gerald Paul;Pizzo, Philip A.;Rubin, Marc;Pellegrin, Jean Luc;Marit, Gerald;Texier, Jeannette;Leng, Bernard
Référence The New England journal of medicine, 318, 25, page (1694-1696)
Publication Publié, 1988-06
;Gaya, Harold;Zinner, Stephen H.;Meunier, Françoise ;Rolston, Kenneth;Bodey, Gerald Paul;Pizzo, Philip A.;Rubin, Marc;Pellegrin, Jean Luc;Marit, Gerald;Texier, Jeannette;Leng, BernardRéférence The New England journal of medicine, 318, 25, page (1694-1696)
Publication Publié, 1988-06
Lettre à l'éditeur
| Résumé : | To the Editor: Antibiotic therapy for patients with fever and neutropenia remains controversial.1 The most recent trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) concluded that ceftazidime given in combination with a full course of amikacin was superior to ceftazidime plus a short course of treatment with amikacin for gram-negative bacillary bacteremias, and that the former combination should be used empirically in febrile patients with neutropenia (Dec. 31 issue).2 The response rate (81 percent) reported with the full-course amikacin regimen is similar to that reported in various studies.3 4 5 6 7 8 9 The poor response rate (48 percent) with. © 1988, Massachusetts Medical Society. All rights reserved. |
